Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ARYx Therapeutics, Inc. (ARYX)
Fremont, CA, US
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +0.00% | -96.55% | -77.27% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+26.7% ★ Q3'10: +75.0% (vs Q3'09)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-2,719.0%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+44.7% Q3'10: +21.9% (vs Q3'09)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.39× Q3'10: -1.59× (vs Q3'09)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2010 actual |
Dec 2011 actual |
|---|---|---|
| Revenue |
—
est.
|
5.00M
est.
|
| EBITDA |
—
est.
|
-1,000.0K
est.
|
| EBIT |
—
est.
|
-1,000.0K
est.
|
| Net Income |
—
est.
|
—
est.
|
| SGA |
—
est.
|
5.81M
est.
|
| EPS |
—
est.
|
—
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-03-10 | KOLLURI KRISHNA KITTU | 10% Owner | S-Sale | D | Common Stock | 4,469,274 | 0.07 | 326.3K | 0 | — | ↗ |
| 2011-03-10 | KERINS PATRICK J | 10% Owner | S-Sale | D | Common Stock | 4,469,274 | 0.07 | 326.3K | 0 | — | ↗ |
| 2011-03-10 | Growth Equity Opportunities Fund, LLC | 10% Owner | S-Sale | D | Common Stock | 4,469,274 | 0.07 | 326.3K | 0 | — | ↗ |
| 2011-03-10 | DRANT RYAN D | 10% Owner | S-Sale | D | Common Stock | 4,469,274 | 0.07 | 326.3K | 0 | — | ↗ |
| 2010-09-30 | SIMON NICHOLAS J III | Director / 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-09-30 | MPM BIOVENTURES III-QP L.P. | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-09-30 | EVNIN LUKE | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-08-13 | SIMON NICHOLAS J III | Director / 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-08-13 | MPM BIOVENTURES III-QP L.P. | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-08-13 | EVNIN LUKE | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 500,000 | 0.50 | 250.0K | 500,000 | — | ↗ |
| 2010-04-30 | SIMON NICHOLAS J III | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 0.88 | 5.9K | 6,666 | — | ↗ |
| 2010-04-30 | SEKHRI PAUL J | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 0.88 | 5.9K | 6,666 | — | ↗ |
| 2010-04-30 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 0.88 | 5.9K | 6,666 | — | ↗ |
| 2010-04-30 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 0.88 | 5.9K | 6,666 | — | ↗ |
| 2010-04-30 | BEIER DAVID W | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 0.88 | 5.9K | 6,666 | — | ↗ |
| 2009-05-22 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 4.00 | 8.00M | 1,340,139 | — | ↗ |
| 2009-04-30 | SIMON NICHOLAS J III | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 3.80 | 25.3K | 6,666 | — | ↗ |
| 2009-04-30 | SEKHRI PAUL J | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 3.80 | 25.3K | 6,666 | — | ↗ |
| 2009-04-30 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 3.80 | 25.3K | 6,666 | — | ↗ |
| 2009-04-30 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 3.80 | 25.3K | 6,666 | — | ↗ |
| 2009-04-30 | BEIER DAVID W | Director | A-Award | A | Stock Option (Right to Buy) | 6,666 | 3.80 | 25.3K | 6,666 | — | ↗ |
| 2008-11-14 | TRAINOR III EUGENE A | 10% Owner | — | I | Common Stock Warrant (Right to Buy) | 1,340,782 | 2.64 | 3.54M | 0 | — | ↗ |
| 2008-11-14 | SIMON NICHOLAS J III | Director / 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 536,313 | 2.64 | 1.42M | 536,313 | — | ↗ |
| 2008-11-14 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 1,214,646 | 2.24 | 2.72M | 3,340,139 | — | ↗ |
| 2008-11-14 | MPM BIOVENTURES III QP LP | 10% Owner | P-Purchase | A | Common Stock | 1,787,710 | 2.20 | 3.93M | 5,364,572 | — | ↗ |
| 2008-11-14 | KOLLURI KRISHNA KITTU | 10% Owner | — | I | Common Stock Warrant (Right to Buy) | 1,340,782 | 2.64 | 3.54M | 0 | — | ↗ |
| 2008-11-14 | KERINS PATRICK J | 10% Owner | — | I | Common Stock Warrant (Right to Buy) | 1,340,782 | 2.64 | 3.54M | 0 | — | ↗ |
| 2008-11-14 | Growth Equity Opportunities Fund, LLC | 10% Owner | — | D | Common Stock Warrant (Right to Buy) | 1,340,782 | 2.64 | 3.54M | 0 | — | ↗ |
| 2008-11-14 | EVNIN LUKE | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 536,313 | 2.64 | 1.42M | 536,313 | — | ↗ |
| 2008-11-14 | DRANT RYAN D | 10% Owner | — | I | Common Stock Warrant (Right to Buy) | 1,340,782 | 2.64 | 3.54M | 0 | — | ↗ |
| 2008-11-14 | Adelman Robert J | Director / 10% Owner | P-Purchase | A | Common Stock Warrants (right to buy) | 364,395 | 2.64 | 962.0K | 364,395 | — | ↗ |
| 2008-08-28 | BEIER DAVID W | Director | A-Award | A | Stock Option (Right to Buy) | 16,666 | 6.33 | 105.5K | 16,666 | — | ↗ |
| 2007-11-13 | SIMON NICHOLAS J III | Director / 10% Owner | C-Conversion | A | Common Stock | 1,571,267 | 0.00 | — | 1,571,267 | — | ↗ |
| 2007-11-13 | ORBIMED ADVISORS LLC | Director | P-Purchase | A | Common Stock | 300,000 | 10.00 | 3.00M | 2,125,493 | — | ↗ |
| 2007-11-13 | MPM BIOVENTURES III QP LP | 10% Owner | C-Conversion | D | Series D Convertible Preferred Stock | 1,125,077 | 0.00 | — | 0 | — | ↗ |
| 2007-11-13 | EVNIN LUKE | 10% Owner | C-Conversion | A | Common Stock | 580,518 | 0.00 | — | 3,276,862 | — | ↗ |
| 2007-11-13 | Adelman Robert J | Director / 10% Owner | C-Conversion | A | Common Stock | 897,866 | 0.00 | — | 1,197,866 | — | ↗ |
| 2007-11-07 | SIMON NICHOLAS J III | Director / 10% Owner | — | I | Series E Convertible Preferred Stock | 580,518 | 0.00 | — | 0 | — | ↗ |
| 2007-11-07 | SEKHRI PAUL J | Director | — | D | Stock Option (Right to Buy) | 15,000 | 1.80 | 27.0K | 0 | — | ↗ |
| 2007-11-07 | ORBIMED ADVISORS LLC | Director | — | I | Series D Convertible Preferred Stock | 604,228 | 0.00 | — | 0 | — | ↗ |
| 2007-11-07 | MPM BIOVENTURES III QP LP | 10% Owner | — | I | Series E Convertible Preferred Stock | 580,518 | 0.00 | — | 0 | — | ↗ |
| 2007-11-07 | Leonard Keith R | Director | — | D | Stock Option (Right to Buy) | 15,000 | 1.80 | 27.0K | 0 | — | ↗ |
| 2007-11-07 | Ekman Lars | Director | — | D | Stock Option (Right to Buy) | 7,500 | 0.90 | 6.8K | 0 | — | ↗ |
| 2007-11-07 | EVNIN LUKE | 10% Owner | — | I | Series D Convertible Preferred Stock | 1,125,077 | 0.00 | — | 0 | — | ↗ |
| 2007-11-07 | Adelman Robert J | Director / 10% Owner | — | D | Stock Option (Right to Buy) | 15,000 | 1.80 | 27.0K | 0 | — | ↗ |
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARYX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
